Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Vision Medicines Inc.
DescriptionSystemically administered mAb targeting beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat geographic atrophy (GA); Treat intermediate age-related macular degeneration (iAMD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today